# SAGA Diagnostics
SAGA Diagnostics AB is a Swedish cancer liquid-biopsy company, founded in Lund in 2016 by Dr Lao Saal and Anthony George as a spin-out from [Lund University](https://www.edgepedia.org/lund-university), which develops ultrasensitive blood tests for detecting and monitoring cancer through circulating tumor DNA (ctDNA); on April 16, 2026 it agreed to be acquired by Roche for up to $595 million, with the platform to be integrated into Roche's affiliate [Foundation Medicine](https://www.edgepedia.org/foundation-medicine).[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) • [2](https://www.innovation.lu.se/en/saga-diagnostics)
| Key facts | |
|---|---|
| Founded | 2016, Lund, Sweden, by Dr Lao Saal and Anthony George[2](https://www.innovation.lu.se/en/saga-diagnostics) |
| Sector | Cancer liquid biopsy and molecular residual disease (MRD) testing[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290) |
| Flagship product | Pathlight, a tumor-informed MRD blood test for early-stage breast cancer, which the company describes as commercially available in the U.S.[4](https://sagadiagnostics.com/) |
| Detection limit | Pathlight detected MRD below 1 part per million ctDNA in the TRACER analysis; the earlier SAGAsafe and SAGAseq platform was reported with limits of detection down to 0.001% mutant allele fraction (equal to 10 parts per million)[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290) • [5](https://www.biospace.com/press-releases/saga-diagnostics-announces-u-s-commercial-launch-of-pathlight-at-asco-2025-setting-a-new-standard-for-ultra-sensitive-and-early-mrd-detection) |
| Documented financing | SEK 106 million (€10.5 million) Series A2, June 29, 2021[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290) |
| Outcome | Definitive merger agreement with Roche for up to $595 million (≈€504 million), announced April 16, 2026, expected to close in Q3 2026[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) • [6](https://oresundstartups.com/e500m-acquisition-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/) |
## Founding and scientific origins
SAGA was founded in 2016 by Dr Lao Saal and Anthony George, based on research from Lund University's Department of Clinical Sciences, and has been a portfolio company of Lund University's innovation system since that year.[2](https://www.innovation.lu.se/en/saga-diagnostics) • [7](https://www.innovation.lu.se/en/article/transforming-cancer-care-saga-diagnostics-test-now-launched-us) The company spun out of Lund University with the goal of quantifying aberrations in DNA, RNA, and ctDNA strands in patients' bloodstreams using massive parallel sequencing and digital PCR.[8](https://www.fiercebiotech.com/medtech/roche-boosts-diagnostics-offering-595m-saga-buyout) It was based at Medicon Village in Lund and was part of the Smile incubator.[9](https://www.mediconvillage.se/news/medicon-village-based-saga-diagnostics-acquired-by-roche-for-595m/) • [6](https://oresundstartups.com/e500m-acquisition-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/)
## Technology and products
**Pathlight**, the company's flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that the company describes as commercially available in the U.S. for patients with early-stage breast cancer.[4](https://sagadiagnostics.com/)
The assay works in two steps. Whole-genome sequencing of a patient's tumor specimen, combined with proprietary algorithms, identifies stable structural variant (SV) breakpoints and builds a personalized genomic fingerprint of the tumor; those breakpoints are then tracked in blood using multiplex digital PCR to detect ctDNA.[5](https://www.biospace.com/press-releases/saga-diagnostics-announces-u-s-commercial-launch-of-pathlight-at-asco-2025-setting-a-new-standard-for-ultra-sensitive-and-early-mrd-detection)
Earlier products included the CE-marked **SAGAsafe** dPCR assays, **SAGAsign** for minimal residual disease monitoring and the **SAGAseq** sequencing platform, built on digital PCR and next-generation sequencing with limits of detection down to 0.001% mutant allele fraction.[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290)
## Clinical evidence
**The TRACER study.** In a retrospective analysis of 100 patients with stage I–III breast cancer of all subtypes receiving neoadjuvant and adjuvant therapy, published in *Clinical Cancer Research* in January 2025, Pathlight showed 100% sensitivity, 100% specificity, and a 13.7-month lead time to recurrence, meaning ctDNA was detected on average more than a year before clinical recurrence.[5](https://www.biospace.com/press-releases/saga-diagnostics-announces-u-s-commercial-launch-of-pathlight-at-asco-2025-setting-a-new-standard-for-ultra-sensitive-and-early-mrd-detection) The baseline detection rate was 96% overall and 94% in estrogen receptor-positive (ER+) breast cancer, and the assay detected MRD below 1 part per million.[5](https://www.biospace.com/press-releases/saga-diagnostics-announces-u-s-commercial-launch-of-pathlight-at-asco-2025-setting-a-new-standard-for-ultra-sensitive-and-early-mrd-detection) These results were reported in company and investor communications rather than in independent coverage.
## Funding and investors
The documented financing in the record is a single round: on June 29, 2021 SAGA raised SEK 106 million (€10.5 million) in a Series A2 financing from existing and new investors.[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290) The company's press release said the round was led by Segulah Medical Acceleration and the Sciety investment syndicate, with support from existing shareholder [Hadean Ventures](https://www.edgepedia.org/hadean-ventures).[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290) Sciety's own later account says the round was led by Sciety, with Segulah Medical Acceleration the largest investor; the two descriptions differ on who led, and the sources do not settle the question.[10](https://sciety.com/sciety-portfolio-company-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/) FSG (Fåhraeus Startup and Growth) held just under 10% of shares as one of the biggest external shareholders, and Lund-ecosystem investors included LU Ventures.[6](https://oresundstartups.com/e500m-acquisition-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/)
No source in the record documents any round before or after the 2021 Series A2, so the company's total funding cannot be stated.
## Business, customers and traction
SAGA offered companion diagnostics and laboratory services for tissue and liquid biopsies to the pharmaceutical industry, healthcare, and academia.[2](https://www.innovation.lu.se/en/saga-diagnostics) At the time of the Series A2 it already had commercial agreements with pharmaceutical partners, key opinion leaders, and clinical laboratories, selling lab services and reagent kits; round proceeds were earmarked for extending the SAGAsafe assay range, commercializing SAGAsign, launching SAGAseq, and establishing CLIA laboratory capabilities.[3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290)
**U.S. commercialization.** SAGA announced the U.S. commercial launch of Pathlight at the 2025 ASCO Annual Meeting in Chicago (May 30 to June 3, 2025).[7](https://www.innovation.lu.se/en/article/transforming-cancer-care-saga-diagnostics-test-now-launched-us) Pathlight was submitted for U.S. reimbursement via the MolDX Program and is analytically validated across multiple cancer types.[7](https://www.innovation.lu.se/en/article/transforming-cancer-care-saga-diagnostics-test-now-launched-us) The company states that Pathlight is covered by Medicare for cancer recurrence monitoring in early-stage breast cancer across all subtypes and is currently available to U.S. patients, with an international launch planned.[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) By the mid-2020s most of SAGA's approximately 100 staff were in the United States, with only a smaller R&D team remaining in Lund.[6](https://oresundstartups.com/e500m-acquisition-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/)
## The 2026 acquisition by Foundation Medicine
On April 16, 2026, Roche entered a definitive merger agreement to acquire SAGA Diagnostics for up to $595 million (reported as up to €504 million), inclusive of commercial and regulatory milestone payments.[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) • [6](https://oresundstartups.com/e500m-acquisition-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/) Because milestone payments are tied to commercial and regulatory outcomes, the eventual price could be considerably lower than the headline figure.[11](https://dealroom.co/news/127397-roche-pays-up-to-595m-for-cancer-detection-startup-saga-diagnostics/)
The transaction was subject to customary closing conditions including regulatory approvals, and was expected to close in Q3 2026 at the latest.[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) After closing, SAGA's tumor-informed MRD platform is to be fully integrated into Foundation Medicine, an independent affiliate of Roche, which plans to use Roche's AXELIOS sequencing and Digital LightCycler PCR platforms to develop a decentralized MRD solution.[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) Investor Sciety described the clinical validation of Pathlight, its U.S. commercial launch, and its Medicare reimbursement for breast cancer as prerequisites for commercial scaling that preceded the deal.[10](https://sciety.com/sciety-portfolio-company-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/) The contrast with the 2021 round is sharp: an up-to-$595 million exit against a €10.5 million Series A2.[1](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/) • [3](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290)
## Positioning against first-generation MRD tests
SAGA argued that structural variants, unlike the single nucleotide variants (SNVs) commonly used by first-generation MRD technologies, are often founding events in tumorigenesis and are conserved through disease progression, making them more stable markers to track.[4](https://sagadiagnostics.com/) The company claimed its platform breaks the 1 part-per-million detection barrier, below the sensitivity of SNV-based first-generation tests, and cited its 94% baseline detection in ER+ breast cancer against first-generation tests that it said struggle to exceed 80% in that population; these figures are the company's own comparison.[4](https://sagadiagnostics.com/) The broader MRD field has been described as crowded and fast-moving.[11](https://dealroom.co/news/127397-roche-pays-up-to-595m-for-cancer-detection-startup-saga-diagnostics/)
## References
1. [Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics' Tumor-Informed MRD Platform](https://sagadiagnostics.com/foundation-medicine-to-strengthen-monitoring-portfolio-with-saga-diagnostics-tumor-informed-molecular-residual-disease-mrd-platform/)
2. [SAGA Diagnostics | Innovation at Lund University](https://www.innovation.lu.se/en/saga-diagnostics)
3. [SAGA Diagnostics raises SEK 106 million (€10.5 million) to accelerate commercialization of ultrasensitive cancer liquid biopsies (Cision)](https://news.cision.com/59-north-communications/r/saga-diagnostics-raises-sek-106-million--10-5-million--to-accelerate-commercialization-of-ultrasensi,c3376290)
4. [SAGA Diagnostics (company website)](https://sagadiagnostics.com/)
5. [SAGA Diagnostics Announces U.S. Commercial Launch of Pathlight at ASCO 2025 (Biospace)](https://www.biospace.com/press-releases/saga-diagnostics-announces-u-s-commercial-launch-of-pathlight-at-asco-2025-setting-a-new-standard-for-ultra-sensitive-and-early-mrd-detection)
6. [€500M Acquisition: SAGA Diagnostics acquired by Foundation Medicine, a subsidiary of Roche (Øresund Startup News)](https://oresundstartups.com/e500m-acquisition-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/)
7. [Transforming Cancer Care: SAGA Diagnostics' Test Now Launched in the U.S. (Innovation at Lund University)](https://www.innovation.lu.se/en/article/transforming-cancer-care-saga-diagnostics-test-now-launched-us)
8. [Roche boosts diagnostics offerings with $595M Saga buyout (Fierce Biotech)](https://www.fiercebiotech.com/medtech/roche-boosts-diagnostics-offering-595m-saga-buyout)
9. [Medicon Village-based Saga Diagnostics acquired by Roche for $595M](https://www.mediconvillage.se/news/medicon-village-based-saga-diagnostics-acquired-by-roche-for-595m/)
10. [Sciety portfolio company Saga Diagnostics acquired by Foundation Medicine, a subsidiary of Roche](https://sciety.com/sciety-portfolio-company-saga-diagnostics-acquired-by-foundation-medicine-a-subsidiary-of-roche/)
11. [Roche pays up to $595M for cancer detection startup SAGA Diagnostics (Dealroom News)](https://dealroom.co/news/127397-roche-pays-up-to-595m-for-cancer-detection-startup-saga-diagnostics/)
---
*Topic: Encyclopedia › Society and history › Economics and business › Business and work › Business and work overview › Companies and corporations › Venture-backed startups and growth companies › Health, biotech, and medtech startups › Diagnostics and genomics companies › Cancer and molecular diagnostics*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026; Oct 11, 2026; Oct 21, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license